The efficacy of using a multiparametric magnetic resonance imaging-based radiomics model to distinguish glioma recurrence from pseudoprogression.

OBJECTIVE: The early differential diagnosis of the postoperative recurrence or pseudoprogression (psPD) of a glioma is of great guiding significance for individualized clinical treatment. This study aimed to evaluate the ability of a multiparametric magnetic resonance imaging (MRI)-based radiomics model to distinguish between the postoperative recurrence and psPD of a glioma early on and in a noninvasive manner. METHODS: A total of 52 patients with gliomas who attended the Hainan Provincial People's Hospital between 2000 and 2021 and met the inclusion criteria were selected for this study. 1137 and 1137 radiomic features were extracted from T1 enhanced and T2WI/FLAIR sequence images, respectively.After clearing some invalid information and LASSO screening, a total of 9 and 10 characteristic radiological features were extracted and randomly divided into the training set and the test set according to 7:3 ratio. Select-Kbest and minimum Absolute contraction and selection operator (LASSO) were used for feature selection. Support vector machine and logistic regression were used to form a multi-parameter model for training and prediction. The optimal sequence and classifier were selected according to the area under the curve (AUC) and accuracy. RESULTS: Radiomic models 1, 2 and 3 based on T1WI, T2FLAIR and T1WI + T2T2FLAIR sequences have better performance in the identification of postoperative recurrence and false progression of T1 glioma. The performance of model 2 is more stable, and the performance of support vector machine classifier is more stable. The multiparameter model based on CE-T1 + T2WI/FLAIR sequence showed the best performance (AUC:0.96, sensitivity: 0.87, specificity: 0.94, accuracy: 0.89,95% CI:0.93-1). CONCLUSION: The use of multiparametric MRI-based radiomics provides a noninvasive, stable, and accurate method for differentiating between the postoperative recurrence and psPD of a glioma, which allows for timely individualized clinical treatment.

MBNL1­AS1 attenuates tumor cell proliferation by regulating the miR­29c­3p/BVES signal in colorectal cancer.

Dysregulation of long non­coding RNAs (lncRNAs) is involved in the development of colorectal cancer (CRC). In the present study, the identification of muscle blind like splicing regulator 1 antisense RNA 1 (MBNL1­AS1) lncRNA was reported. Firstly, Cell Counting Kit­8, EdU and colony formation assays were uesed to explore the role of MBNL1­AS1 in regulating the proliferation of CRC cells. According to TCGA database, it was found that MBNL1­AS1 was correlated with microRNA (miR)­29c­3p and blood vessel epicardial substance (BVES) expression in CRC cells. Then, the regulation among MBNL1­AS1, miR­29C­3P and BVES was detected by dual luciferase reporter assay and the function of MBNL1­AS1/miR­29C­3P/BVES axis was explored by rescue assay. The results demonstrated that MBNL1­AS1 expression was decreased in CRC and was associated with the size of tumors derived from patients with CRC. Functionally, the upregulation of MBNL1­AS1 suppressed CRC cell proliferation in vitro and inhibited tumor growth in vivo, while knockdown of MBNL1­AS1 expression caused the opposite effects. MBNL1­AS1 expression correlated with BVES expression in CRC tissues and MBNL1­AS1 enhanced the stability of BVES mRNA by functioning as a competing endogenous RNA to sponge miR­29c­3p; the latter directly targeted MBNL1­AS1 and BVES mRNA 3'UTR. Collectively, the results indicated that MBNL1­AS1 suppressed CRC cell proliferation by regulating miR­29c­3p/BVES signaling, suggesting that the MBNL1­AS1/miR­29c­3p/BVES axis may be a potential therapeutic target for CRC.

Investigation of dacomitinib on reducing cell necrosis and enhancing cell apoptosis in C6 glioma rat model by MRI.

BACKGROUND: Glioma is one of the most epidemic and obstinate types of cancer in the central nervous system (CNS) with poor survival rate. Dacomitinib inhibited cell viability and proliferation of epidermal growth factor receptor (EGFR)-amplified glioma. In the present study, the regional effects of Dacomitinib on tumor necrosis was investigated. METHODS: A C6 rat glioma model was evaluated using proton magnetic resonance spectroscopy (1H-MRS), diffusion weighted imaging (DWI), and morphological T2-weighted imaging (T2W). The effects of Dacomitinib on glioma cells were investigated using methods of immunohistochemistry and Hematoxylin and Eosin (H&E) staining. RESULTS: The obtained data indicated that metabolite ratios were significantly decreased (all P<0.05) in the Dacomitinib-treated group compared with C6 glioma control group. The ADC value of necrotic core in Dacomitinib group was significantly lower than that in control group. In addition, the expression of Ki-67 in Dacomitinib-treated group (50.32 ± 5.61) was significantly lower than that in control group (P<0.05). The apoptotic index (AI) (28.01 ± 2.37) in Dacomitinib-treated group was significantly higher than that in control group (11.58 ± 3.17). CONCLUSION: The results demonstrated that the Dacomitinib could suppress glioma cell necrosis and proliferation.

MiR-382 functions as tumor suppressor and chemosensitizer in colorectal cancer.

Increasing evidence suggests that microRNAs (miRNAs) play a critical role in tumorigenesis. Decreased expression of miR-382 has been observed in various types of cancers. However, the biological function of miR-382 in colorectal cancer (CRC) is still largely unknown. Here, we found that miR-382 was down-regulated in human colorectal cancer tissues and cell lines associated with it. MiR-382 inhibited colorectal cancer cell proliferation, migration, invasion, and enhance chemosensitivity. Furthermore, we identified Krüppel-like factor 12 (KLF12) and homeodomain-interacting protein kinase 3 (HIPK3) as the target of miR-382, and miR-382 rescued the promotion effect of KFL12 on migration and enhanced chemosensitivity in colorectal cancer cell lines. Collectively, these findings revealed that miR-382 inhibits migration and enhances chemosensitivity by targeting KLF12 and HIPK3 in colorectal cancer. These findings might serve as a tumor suppressor in CRC.

Comparison of MRI, CT and 18F-FDG PET/CT in the diagnosis of local and metastatic of nasopharyngeal carcinomas: an updated meta analysis of clinical studies.

BACKGROUND: A meta-analysis was conducted to evaluate the accuracy of MRI, CT and FDG PET/CT in TNM stage of nasopharyngeal carcinoma patients (NPC). METHODS: Through a search of studies from 1996 to April 2015, pooled estimated sensitivity, specificity, pooled diagnostic odds ratio (DOR), summary receiver operating characteristic (SROC) curves and Q*-index were calculated. RESULTS: Totally 23 studies were included for analysis. In T stage, the pooled sensitivity, specificity, DOR and SROC of MRI were 0.95 (95% CI 0.93-0.97), 0.76 (95% CI 0.71-0.80), 86.85 (16.36-461.06) and 0.9213 (SE 0.0372) respectively. The pooled sensitivity, specificity, DOR and SROC of CT were 0.84 (95% CI 0.79 to 0.88), 0.80 (95% CI 0.71 to 0.88), 6.32 (1.17 to 34.02) and 0.7215 (SE 0.054) respectively. The pooled sensitivity, specificity, DOR and SROC of FDG PET/CT were 0.85 (95% CI 0.76 to 0.91), 0.91 (95% CI 0.84 to 0.96) and 0.8673 (SE 0.0311). In N stage, the pooled sensitivity, specificity, DOR and SROC of MRI were 0.88 (95% CI 0.85-0.90), 0.95 (95% CI 0.93-0.97), 93.68 (23.21-379.69) and 0.9153 (SE 0.099) respectively. The pooled sensitivity, specificity, DOR and SROC of CT were 0.92 (95% CI 0.88-0.95), 0.93 (0.76-0.99), 93.81 (22.39-393.03) and 0.8872 (SE 0.0520) respectively. The pooled sensitivity, specificity, DOR and SROC of FDG PET/CT were 0.88 (95% CI 0.85-0.90), 0.95 (95% CI 0.93-0.97), 93.88 (23.21-379.69) and 0.9153 (SE 0.0299) respectively. In M stage, the pooled sensitivity and specificity of MRI were 0.53 (95% CI 0.35-0.70) and 0.99 (95% 0.95-1.00). The pooled sensitivity and specificity of CT were 0.80 (95% CI 0.44-0.97) and 0.93 (95% CI 0.86-0.97) respectively. The pooled sensitivity, specificity and SROC of FDG PET/CT were 0.82 (95% 0.74-0.88), 0.98 (95% CI 0.96-0.99) and 0.9002 (SE 0.075) respectively. CONCLUSION: The analysis suggested that MRI had good accuracy in diagnosis of T stage. Whereas CT is currently a good performance in diagnosis of N stage, FDG PET/CT shows good accuracy in diagnosis of M stage.

Diagnostic Value of Magnetic Resonance Spectroscopy in Radiation Encephalopathy Induced by Radiotherapy for Patients with Nasopharyngeal Carcinoma: A Meta-Analysis.

In this study, articles in English and Chinese were selected from available electronic databases prior to September 2014. The metabolic concentrations and patterns of N-acetylaspartic acid (NAA), Choline (Cho), Creatine (Cr), NAA/Cr, NAA/Cho, and Cho/Cr ratios in radiotherapy-induced radiation encephalopathy by proton magnetic resonance spectroscopy were extracted. A meta-analysis was performed to quantitatively synthesize findings of these studies. Weighted mean difference (WMD) and 95% confidence intervals (95%CIs) were calculated using random or fixed effective models. Heterogeneity between studies was assessed using the Cochrane Q test and I (2) statistics. The results indicated that a total of 4 researches involving 214 patients met inclusion criteria. Depending on methodologies of selected studies, control groups were referred to as healthy subjects. The combined analysis revealed that there was no significant difference in value of Cr between radiotherapy group and healthy control group (WMD = -1.483, 95% CI: -67.185-64.219, p = 0.965). However, there were significant difference in values of NAA (WMD = -18.227, 95%CI: -36.317--0.137, p = 0.048), Cho (WMD = 38.003, 95%CI: 5.155-70.851, p = 0.023), NAA/Cr (WMD = -1.175, 95%CI: -1.563--0.787, p = 0.000), NAA/Cho (WMD = -1.108, 95%CI: -2.003-0.213, p = 0.015), and Cho/Cr (WMD = -0.773, 95%CI: 0.239-1.307, p = 0.005). In conclusion, MRS can be regarded as an effective and feasible imaging test for radiotherapy-induced radiation encephalopathy in NPC patients.

Correlation of CT perfusion images with VEGF expression in solitary brain metastases.

OBJECTIVES: To obtain permeability surface (PS) values using multi-slice helical CT perfusion imaging and to evaluate the spatial distribution correlation between PS values and vascular endothelial growth factor (VEGF) expression in solitary brain metastases. METHODS: Imaging was performed on 21 patients, PS values being calculated from the central, border and peripheral parts of tumours. VEGF expression was determined by immunohistochemical staining. RESULTS: Rim enhancement was found in 16 cases, the border of the tumour featuring PS elevation with high VEGF expression in 13 cases. In the 5 cases with nodular enhancement, the border and the central part had high permeability and VEGF expression was high in all cases, the correlation being significant (P<0.01) . CONCLUSION: VEGF expression in brain metastases positively correlates with PS values from CT perfusion imaging, so that the latter can be used in the surveillance of angiogenic activity in brain metastases.

[A new alkaloids isolated from tetraploidy banlangen].

AIM: To investigate the chemical constituents of tetraploidy Banlangen (Isatis indigotica Fort.). METHODS: Compounds were separated by chromatography on silica gel. Their structures were determined by spectral analysis and chemical evidence. RESULTS: Three compounds were isolated. Their structures were identified as (E)-2-[(3'-indole) cyanomethylene]-3-indolinone (I), 2-(4-hydroxy-3-methoxyphenyl)-4-[(4-hydroxy-3-methoxy-phenyl)-methyl]-3- hydroxymethyl-tetrahydro-furan (II) and 2-methoxy-4-[tetrahydro-4-[(4-hydroxy-3-methoxy-phenyl)-methyl]-3- hydroxymethyl-2-furanyl] phenyl-1-O-beta-D-glucopyranoside (III). CONCLUSION: Compound I is a new compound.